Cardiac biomarkers are protein-based observable substances used as an indicator of biologic state, also called cardiac markers. These biomarkers are released into the bloodstream when heart is stressed, or its muscles are damaged. They includes different type of hormones, enzymes, and proteins, for instance cardiac troponins, ischemia-modified albumin (IMA), creatine kinase (CK), and myoglobin. These are used as risk stratification for many cardiovascular diseases (CVDs), which include congestive heart failure, myocardial infraction, acute coronary syndrome (ACS) among others.
The key features are included quick outcomes, cost effective, high accuracy, non-invasive and economic pricing of cardiac point of care (POC) testing.
According to study, “Global Cardiac Biomarkers Market Size study, by type (Myocardial muscle Creatine Kinase, Myoglobin, Troponins (T and I), Ischemia Modified Albumin (IMA), Brain Natriuretic Peptide (BNPs) or NT-proBNP and Others) Application (myocardial infarction, congestive heart failure, acute coronary syndrome, Atherosclerosis, other applications) Location of Testing (point of care testing and laboratory testing) and Regional Forecasts 2018-2025.” the key companies operating in the global cardiac biomarkers market are Roche Diagnostics Corp., Siemens Healthcare GmbH, Abbott Laboratories Inc., Alere Inc., F. Hoffmann-La Roche Ltd., Tosoh Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., Becton Dickinson and Company, Randox laboratories, Johnson and Johnson, BioMerieux SA, Thermo Fisher Scientific Inc., Olympus Corporation, Beckman Coulter Inc., BG Medicines, Boditech Med Inc., Ortho-Clinical Diagnostics, Inc., Quidel Corporation, Response Biomedical Corp., BG Medicine, Inc., Trivitron Healthcare, Trinity Biotech. The key companies are focusing on innovative technologies for instance automated, multi-assay by combinations of cardiac biomarkers & point-of-care (PoC) cardiac biomarker devices.
Based on type, cardiac biomarkers market is segmented into myocardial muscle Creatine Kinase (CK-MB), Myoglobin, Troponins (T and I), Natriuretic peptides – B-type Natriuretic Peptide (BNP) & N-terminal pro b-type Natriuretic peptide (NT-proBNP), LDH isoenzymes, Heart-type Fatty Acid Binding Protein (H-FABP), and Ischemia Modified Albumin (IMA). Troponins T and I holds major share in market owing to its prodigious specificity and ability to accurately identify the cardiac events of Acute Coronary Syndrome (ACS). Based on application, market is segmented into myocardial infarction, acute coronary syndrome, cardiomyopathy, myocarditis, ischemia, congestive heart failure and atrial fibrillation. Based on location of testing, market is segmented into point of care testing and laboratory testing. In addition, based on end-user, market is segmented into hospitals & clinics and diagnostics laboratories.
The cardiac biomarkers market is driven by increase in prevalence of cardiovascular diseases, followed by rise in point of care (POC) testing, increase in funding from public & private organizations for research & development (R&D), rise in awareness towards cardiac diagnostics solutions, high demand for cardiac testing, growth in patient population and technological advancements using cardiac biomarkers combinations. However, poor reimbursement policies and stringent regulation may impact the market. Moreover, personalized medicine, future developments in novel cardiac biomarkers and POC testing using cardiac biomarkers are key opportunities for market.
Based on geography, the North-American region holds major share, followed by European region in cardiac biomarkers market owing to lack of physical activity & unhealthy diet and high cardiovascular diseases prevalence rate in the region. The Asian-Pacific region is expected to witness higher growth rate due to modernization, increase in affordability for advanced cardiac treatments and rise in disposable incomes over the forecast period.
For more information, click on the link below:
Ankur Gupta, Head Marketing & Communications